Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Litorina V and the Bergfalk group
Mandate

Vinge has advised Litorina V and the Bergfalk group

June 15, 2018 Banking and Finance

Vinge has advised Litorina V and the Bergfalk group in connection with the acquisition of Johan i Hallen i Göteborg AB, a leading Swedish distributor within fresh food with focus on meat.

The company has a turnover of over SEK 640 million and offers its products in Sweden. The company's former main owners and management will remain as significant owners going forward. Through the transaction a partnership is established between the Bergfalk-group and Johan i Hallen creating one of the leading specialist distributors within fresh food with focus on meat, fish and shellfish.

Vinge’s team consisted of partner Jonas Johansson together with the associates Carl Sander and Martin Cronsioe (M&A), Sara Strandberg and Sophia Holm (employment), Kristoffer Larson (real estate), Arvid Axelryd (IP) and Johan Cederblad (environment. Johan Wahlbom provided competition law advice. Partner Louise Brorsson Salomon and associate Sebastian Frisk assisted with the financing.
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024